Valuing Your Pipeline: How Branded Generic Competition Destroys Innovator Revenue — and When
The most dangerous competitor to a blockbuster drug may not be a rival molecule. It may be the same moleculesold under a different name.
For years, pharmaceutical companies have valued pipelines with a familiar formula: estimate peak sales, apply launc…
